- Vienna '18
- Athens 2019
- ESCRS Player
- On Demand
- ESCRS iLearn
- ESCRS YO's
First Author: C.Menezes PORTUGAL
Co Author(s): J. Serino J. Lemos P. Moreira B. Vieira P. Rodrigues N. Martins
Back to previous
To report the safety, efficacy, predictability and stability of the Artiflex iris-fixated intraocular lens in myopic phakic eyes.
Department of Ophthalmology, Hospital Pedro Hispano, Matosinhos, Portugal
A retrospective non-controlled analysis of all patients submitted to Artiflex phakic intraocular lens (PIOL) implantation between May 2011 and May 2012, with a minimum follow-up time of 6 months, was performed. Uncorrected distance visual acuity (UVDA), best spectacle visual acuity (BSCVA), refraction, endothelial cell count and complications were registered to evaluate safety, efficacy, predictability and stability.
27 eyes of 18 patients with a mean spherical equivalent of -8,63D, ranging from -14,50D to -3,75D were analyzed. The mean follow-up time was 11 months. The mean log-Mar BSCVA improved from 0,07 ±0,06 D pre-operatively to 0,02D ±0,03D post-operatively with a safety index of 1,13 ± 0,14D. One Snellen line or more of BSCVA was gained in 74,1% of patients and two or more lines in 14,8%. The post-operative mean log-Mar UDVA was 0,02 and statistically not different from the preoperative BSCVA (p=0,74) with a efficacy index of 0,98 ±0,24 D. 88,9 of the eyes operated had post-operatively SE within +/- 0,5D and 96,3% between +/- 1D. The spherical equivalent and the UDVA remained stable since the first week of follow up and the BSCVA since the first month (p>0,05). The mean endothelial cell loss was 2,74%. The main complications registered were lens pigment precipitates which did not compromise visual acuity (n=3), intraocular pressure elevation (n=1), sectorial iris atrophy (n=1) and necessity of lens explantation in the context of inadequate UDVA due to astigmatism.
Implantation of Artiflex PIOLs in resulted in a predictable, effective, stable and safe correction of refractive error in myopic eyes.